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Figure 1
Results of Serum Speciﬁc IgE (Immunocap) testing of tree nuts.
Component Reference Range
Almond IgE <0.35 KU/L 3.55 (H)
Almond Class 0 3 (H)
Brazil Nut IgE <0.35 KU/L 1.28 (H)
Brazil Nut Class 0 2 (H)
Cashew Nut IgE <0.35 KU/L 3.86 (H)
Cashew Nut Class 0 3 (H)
Hazel Nut IgE <0.35 KU/L 13.5 (H)
Hazel Nut Class 0 3 (H)
Macadamia Nut IgE <0.35 KU/L 0.74 (H)
Macadamia Nut Class 0 2 (H)
Peanut IgE <0.35 KU/L 1.56 (H)
Peanut Class 0 2 (H)
Pecan Nut IgE <0.35 KU/L 4.68 (H)
Pecan Nut Class 0 3 (H)
Pistachio IgE <0.35 KU/L 4.16 (H)
Pistachio Class 0 3 (H)
Walnut IgE <0.35 KU/L 35.60 (H)
Walnut Class 0 4 (H)
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previously reported on the role of dose intensity in a group of
112 patients (pts) with AML (n¼95) and MDS (n¼17) given
SCT with different regimens between 1999 and 2004 (Leu-
kemia 2006). Overall survival (OS) was similar with MAC and
RIC in pts given SCT in remission, but was inferior in pts given
RIC in active disease due to high relapse rates. We have now
updated SCT outcomes in the same cohort with a median
follow up of 10 years (8.5-12.5) in order to verify the original
ﬁndings with long follow up. The median age was 50 years
(18e70). 58 pts had active disease at SCT. The donor was
HLA-matched sibling (n¼58), or matched-unrelated (n¼54).
45 pts met eligibility criteria for standard MAC and were
given intravenous busulfan (ivBu, 12.8 mg/kg) and cyclo-
phosphamide (BuCy). 67 pts were considered non-eligible
for standard MAC and were given RIC with ﬂudarabine and
ivBu (6.4 mg/kg, FB2, n¼41) or reduced toxicity conditioning
(RTC) with ﬂudarabine and myeloablative doses of ivBu (12.8
mg/kg, FB4, n¼26). In all, 38 pts are alive and 74 have died, 48
relapse, 26 non-relapse mortality (NRM). MAC and RIC/RTC
had similar outcomes when leukemia was in remission at
SCT; 10-year OS been 47%, 50% and 47% after BuCy, FB4, and
FB2, respectively (p¼0.97). OS rates of pts with active disease
at SCT was 43%, 19% and 0%, respectively (p¼0.01) suggesting
an advantage for more intense regimens in this setting.
Relapse rates were higher after RIC/RTC than MAC
throughout the follow-up period. The rate was 30% and 18%,
1 year after SCT (p¼0.03), 37% and 20% after 2 years (p¼0.08),
49% and 27% after 5 years (p¼0.02) and 51% and 29% after 10
years (p¼0.02), respectively. NRM rates were higher after
MAC than RIC/RTC in the initial 2 years after SCT but
approached each other in the late post SCT course. NRM rate
was 22% and 9%, 1 year after SCT (p¼0.05), 22 and 10% after 2
years (p¼0.08), 22% and 15% after 5 years (p¼0.27), and 27%
and 19% after 10 years (p¼0.35), respectively. Thus, OS was
similar within the ﬁrst 2 years after SCT, 56% and 52% after
MAC and RIC/RTC, respectively (p¼0.86), but there was a
trend for better OS after MAC later on, 51% and 36%, 5 years
after SCT (p¼0.26) and 44% and 31%, 10 years after SCT
(p¼0.22), respectively. In conclusion, with long-term follow-
up ofmore than 10 years, RIC/RTC is an acceptable alternative
to MAC in ineligible pts. NRM is lower after RIC/RTC in the
early post SCT period, but late NRM negates this early
advantage. Relapse rates are higher after RIC/RTC throughout
the course. Due to these observations it seems an advantage
of MAC may become apparent 5-10 years after SCT. RIC/RTC
studies may need to be revisited with long (> 10 years)
follow up.210
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Background: Food allergy in children in the United States is
estimated to be approximately 8% and increasing yearly with
approximately 40% causing severe reactions requiring med-
ical intervention and possibly death. BMT donors are
screened for drug and food allergy because concern of po-
tential passive transfer of allergy with hematopoietic stem
cell transplantation.
Case report: We report a case of a 15 year old boy with
relapsed AML who underwent matched-related bone
marrow transplant from his non-identical twin brother
after myeloablative conditioning therapy with Busulfan-
Cyclophosphamide. His brother has a history of anaphy-
laxis to walnuts and pecans with conﬁrmatory skin testing
being positive for cashews, ﬁlbert nuts, pecans, and wal-
nuts prior to bone marrow transplant. Before trans-
plantation, our patient said he was able to eat tree nuts
including walnuts without difﬁculty. After the transplant
the patient avoided tree nuts and had skin prick testing
which showed large positives to tree nuts. Serum speciﬁc
IgE (sIgE) by Immunocap to tree nuts and peanut at his
one year post transplant evaluation showed (Figure 1) he
had a > 95% risk for anaphylaxis to walnuts with sIgE
positive to all other tested tree nuts and peanut. A diag-
nostic food challenge was not performed because of this
risk.
Conclusion: Bone marrow transplant physicians should be
more mindful of donor reported food allergies and
consider referral to an allergist for testing after trans-
plantation as passive transfer of IgE mediated food allergies
can occur.
